Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Study of SME3110 (Fluvoxamine Maleate) in Pediatric/Adolescent Subjects With Obsessive Compulsive Disorder

NCT01933919 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT01933919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01933919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Study of SME3110 (Fluvoxamine Maleate) in Pediatric/Adolescent Subjects With Obsessive Compulsive Disorder
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Completed
Start date
August 14, 2013
Completion date
July 1, 2016
Enrollment
38 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

obsessive compulsive disorder